Eli Lilly initiates head-to-head clinical trial for psoriasis med

Eli Lilly and Company announced the initiation of the IXORA-R head-to-head clinical trial, designed to evaluate superiority between Taltz and Tremfya in adult patients with moderate-to-severe plaque psoriasis. The IXORA-R study will be the first H2H trial between an IL-17 and IL-23 using the Psoriasis Area Severity Index 100 score as the primary endpoint. The IXORA-R study, which is set to be completed by the end of 2019, aims to enroll 960 patients and is a 24-week multicenter, randomized, blinded, parallel-group study comparing the efficacy and safety of Taltz to Tremfya in patients with moderate-to-severe plaque psoriasis. The primary endpoint of the study is the proportion of patients who achieve 100% improvement from their baseline as measured by PASI 100 at week 12. Secondary endpoints include: the proportion of patients achieving PASI 75 as early as week 2 and PASI 100 at weeks 4, 8 and 24; and the proportion of patients achieving a Static Physician Global Assessment score of 0 at week 12.
https://thefly.com/landingPageNews.php?id=2787937